AACE to examine role of SGLT2 inhibitors in diabetic ketoacidosis

The American Association of Clinical Endocrinologists will host a conference this fall to explore the incidence of diabetic ketoacidosis in patients treated with SGLT2 inhibitors, following an FDA warning and recent reports linking the drug to the condition.

The AACE Scientific and Clinical Review of DKA and the Effects of SGLT2 Inhibitors will take place Oct. 24-25, 2015 at the Grand Hyatt DFW in Dallas, and will include scientists and diabetes experts examining available data and providing recommendations for clinicians and patients.

The FDA released a warning in May stating the medications Invokana (canagliflozin, Janssen), Farxiga (dapagliflzin, Astra Zeneca) and Jardiance (empagliflozin, Boehringer Ingelheim) may lead to ketoacidosis. It said, however, that patients should not change or stop their medications without talking to their physician.

From March 2013 to June 2014, 20 cases of acidosis, identified as diabetic ketoacidosis (DKA), ketoacidosis or ketosis, were identified in patients taking SGLT2 inhibitors. All cases required visits to the ED or hospitalization. Additional reports of DKA and ketoacidosis in patients treated with these medications have been reported since June 2014, according to the FDA.

“AACE’s responsibility to its members and their diabetes patients is to conduct a complete, objective and balanced evaluation of the data and investigate any knowledge gaps before issuing our recommendations,” George Grunberger, MD, FACP, FACE, AACE president, said in a press release announcing the meeting. “There are still unanswered questions to answer before we draw any definitive conclusions on the subject, and that is what this conference is designed to do.”

The American Association of Clinical Endocrinologists will host a conference this fall to explore the incidence of diabetic ketoacidosis in patients treated with SGLT2 inhibitors, following an FDA warning and recent reports linking the drug to the condition.

The AACE Scientific and Clinical Review of DKA and the Effects of SGLT2 Inhibitors will take place Oct. 24-25, 2015 at the Grand Hyatt DFW in Dallas, and will include scientists and diabetes experts examining available data and providing recommendations for clinicians and patients.

The FDA released a warning in May stating the medications Invokana (canagliflozin, Janssen), Farxiga (dapagliflzin, Astra Zeneca) and Jardiance (empagliflozin, Boehringer Ingelheim) may lead to ketoacidosis. It said, however, that patients should not change or stop their medications without talking to their physician.

From March 2013 to June 2014, 20 cases of acidosis, identified as diabetic ketoacidosis (DKA), ketoacidosis or ketosis, were identified in patients taking SGLT2 inhibitors. All cases required visits to the ED or hospitalization. Additional reports of DKA and ketoacidosis in patients treated with these medications have been reported since June 2014, according to the FDA.

“AACE’s responsibility to its members and their diabetes patients is to conduct a complete, objective and balanced evaluation of the data and investigate any knowledge gaps before issuing our recommendations,” George Grunberger, MD, FACP, FACE, AACE president, said in a press release announcing the meeting. “There are still unanswered questions to answer before we draw any definitive conclusions on the subject, and that is what this conference is designed to do.”